Clinical Trial Update: Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 trial assessing ranolazine treatment to reduce ischemic myocardium in patients with acute myocardial ischemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Ischemia

Drugs mentioned

• Ranolazine (ranolazine)

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Coronary Artery Disease, Acute Myocardial Ischemia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-01-12